Panacea Biotec has launched its ViLACT brand in India for the treatment of uncontrolled type 2 diabetes mellitus patients with HbA1c >6.5%.
The four formulations are vildagliptin 50 mg, vildagliptin 50 mg + metformin HCL 500 mg, vildagliptin 50 mg + metformin HCL 850 mg and vildagliptin 50 mg + metformin HCL 1,000 mg. The new drug will provide the physician a lot of options to bring down the burden of diabetes.
As per the AIOCD MAT October 2019 data, the total market size of this molecule and its combination is Rs.969 crore and is growing at the rate of 4 per cent.
Company Profile : Panacea Biotec Ltd